Rallybio Corporation (RLYB)
| Market Cap | 46.39M |
| Revenue (ttm) | 858,000 |
| Net Income (ttm) | -8.98M |
| Shares Out | 5.29M |
| EPS (ttm) | -1.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,770 |
| Open | 8.79 |
| Previous Close | 8.78 |
| Day's Range | 8.68 - 9.07 |
| 52-Week Range | 2.16 - 11.49 |
| Beta | -1.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 11, 2026 |
About RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to ... [Read more]
Financial Performance
In 2025, Rallybio's revenue was $858,000, an increase of 34.91% compared to the previous year's $636,000. Losses were -$8.98 million, -84.46% less than in 2024.
Financial StatementsNews
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
Rallybio Corporation (NASDAQ: RLYB) shares are up Monday following a merger agreement with Candid Therapeutics Inc.
Rallybio Transcript: M&A announcement
The merger creates a leading TCE therapeutics company for autoimmune diseases, combining robust pipelines and over $500 million in capital to advance multiple candidates into late-stage clinical trials. The combined entity aims for global leadership and accelerated development timelines.
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a lead...
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026
Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Announces Reverse Stock Split of Common Stock
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an ...
Rallybio Transcript: EGM 2026
Stockholders approved an amendment for a reverse stock split at a ratio between 1:5 and 1:20, with a quorum of 82.81% present. Final results will be disclosed in a Form 8-K within four business days.
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio Corporation RLYB agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals...
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Transcript: The Citizens JMP Life Sciences Conference 2025
RLYB212 was discontinued due to clinical limitations, shifting focus to RLYB116, a novel C5 inhibitor targeting rare diseases like APS, with adaptive clinical trials and data readouts expected in Q3 and Q4. Preclinical ENPP1 inhibitor data and financial updates are also anticipated soon.
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
Rallybio Corporation RLYB on Tuesday discontinued the RLYB212 program to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Transcript: TD Cowen 45th Annual Healthcare Conference
Three rare disease programs are advancing, with the FNAIT prevention trial enrolling its first pregnant patient and data expected in 2Q/3Q. The complement Factor V inhibitor and ENPP1 inhibitor are progressing, targeting significant unmet needs and market opportunities.
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...